3 healthcare shares to buy and hold for a decade

One area of the market which I think has strong long-term growth potential is the healthcare sector.

Thanks to ageing populations and increased chronic disease burden, demand for healthcare services is expected to grow strongly over the next two decades.

This could make the sector a great place to make a buy and hold investment.

Here are three top shares that I would consider buying:

Cochlear Limited (ASX: COH)

As the global population grows older I believe this hearing solutions company will benefit from increasing demand for its products. This demand, and its industry-leading products, could put Cochlear in a position to continue delivering above-average profit growth for a long time to come. Its shares may have been on a tear over the last 12 months, but I believe they are still good value for patient buy and hold investors.

CSL Limited (ASX: CSL)

I think that this biotherapeutics company’s outstanding half-year result in February showed investors why it is regarded as one of the highest quality companies in Australia. As well as that, I believe the result demonstrated the significant potential of its fledgling Seqirus influenza business. All in all, I believe the emergence of Seqirus should support the growth being exhibited by its core business, allowing for solid profit growth over the coming years.

Pro Medicus Limited (ASX: PME)

I believe the health imaging IT provider’s Visage 7 technology has enormous potential. Visage 7 allows radiologists and physicians to visually assess a patient’s complete imaging history, along with the flexibility to access, finely choreograph, and immediately display any combination of imaging components. The technology has been attracting a lot of interest from some major players in the healthcare sector, which I believe is a testament to the product’s quality.

Finally, here are three more top shares that could be great buy and hold investment ideas.

3 top buy and hold shares for April

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended PRO Medicus Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.